Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 4/20 | 0.48 |
| ▸ | PAK3 | O75914 | 3/20 | 0.48 |
| ▸ | PAK2 | Q13177 | 3/20 | 0.48 |
| ▸ | PKN1 | Q16512 | 3/20 | 0.48 |
| ▸ | PAK4 | O96013 | 2/20 | 0.48 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.48 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.48 |
| ▸ | TNK2 | Q07912 | 11/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
| ▸ | CCND2 | P30279 | 1/20 | 0.42 |
| ▸ | CCND3 | P30281 | 1/20 | 0.42 |
| ▸ | WEE1 | P30291 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035743 | 0.80 | PAK3 (0.47) | PAK1PAK3PAK2PKN1PAK4 | |
| SCHEMBL15035041 | 0.77 | PAK3 (0.47) | PAK1PAK3PAK2PKN1PAK4 | |
| SCHEMBL15034829 | 0.77 | PAK3 (0.47) | PAK1PAK3PAK2PKN1PAK4 | |
| SCHEMBL15035907 | 0.77 | PAK4 (0.47) | PAK1PAK3PAK2PKN1PAK4 | |
| SCHEMBL15035691 | 0.76 | PAK3 (0.47) | PAK1PAK3PAK2PKN1PAK4 | |
| SCHEMBL13553706 | 0.75 | PAK3 (0.48) | PAK1PAK3PAK2PKN1PAK4 | |
| SCHEMBL15785353 | 0.74 | PAK1 (0.50) | PAK1PAK3PAK2PKN1PAK4 | |
| SCHEMBL15035559 | 0.73 | CDK4 (0.48) | PAK1PAK3PAK2PKN1PAK4 | |
| SCHEMBL15036165 | 0.72 | PAK3 (0.48) | PAK1PAK3PAK2PKN1PAK4 | |
| SCHEMBL15035064 | 0.72 | PKN1 (0.47) | PAK1PAK3PAK2PKN1PAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231348-A1 | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231348-A1 | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231348-A1 | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK3, PAK5 | PAK1 6/4885PAK3 2/4885PAK2 1/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | PAK1 4/4885PAK3 6/4885PAK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.